PleoPharma

PleoPharma is a clinical-stage development company in the field of neuropsychology and addiction, focusing on finding solutions for individuals suffering from cannabis addiction and other cannabis-related health issues. The company’s PP-01 is a dual-mechanism investigational product targeting inhibited CB1 receptors and neurotransmitter imbalances within the mesolimbic reward pathway. PP-01 is entering Phase 3 and has the potential to become the first-of-its-kind treatment to alleviate withdrawal symptoms experienced by many patients with cannabis use disorder (dependence/addiction). PP-01 is designed as a once-daily oral product with rapid onset, excellent safety, and tolerability.